In addition to lipid kinase activity, the class-I PI 3-kinases also function as protein kinases targeting regulatory autophosphorylation sites and exogenous substrates. The latter include a recently identified regulatory phosphorylation of the GM-CSF/IL-3 bc receptor contributing to survival of acute myeloid leukaemia cells. Previous studies suggested differences in the protein kinase activity of the 4 isoforms of class-I PI 3-kinase so we compared the ability of all class-I PI 3-kinases and 2 common oncogenic mutants to autophosphorylate, and to phosphorylate an intracellular fragment of the GM-CSF/IL-3 bc receptor (bic). We find p110a, p110b and p110c all phosphorylate bic but p110d is much less effective. The two most common oncogenic mutants of p110a, H1047R and E545K have stronger protein kinase activity than wildtype p110a, both in terms of autophosphorylation and towards bic. Importantly, the lipid kinase activity of the oncogenic mutants is still inhibited by autophosphorylation to a similar extent as wildtype p110a. Previous evidence indicates the protein kinase activity of p110a is Mn 2+ dependent, casting doubt over its role in vivo. However, we show that the oncogenic mutants of p110a plus p110b and p110c all display significant activity in the presence of Mg
Introduction
The class 1 phosphoinositide 3-kinases (PI 3-kinases) play a critical role in pathways regulating functions such as cell metabolism, cell growth and survival, cytoskeletal rearrangements and cell movement [1, 2] . The class 1a PI 3-kinases are heterodimers consisting of a regulatory (or adapter) subunit (most commonly p85a, but also p85b, p55a, p50a or p55c) coupled to a 110 kDa catalytic subunit (p110a, b, or d). The class 1b PI3-K is also a dimer composed of a regulatory subunit (p101, p84 or p87PIKAP) coupled to the catalytic subunit (p110c) [3] [4] [5] . Recently a range of oncogenic mutations have been identified in PIK3CA (p110a) and PIK3R1 (p85a) [6, 7] and these result in elevation of the lipid kinase activity [8, 9] .
The PI 3-kinases are named for their lipid kinase activity, phosphorylating the 39 position of the inositol ring in phosphatidylinositol (PtdIns) lipids and the consequences of this activity are well defined [10] [11] [12] . However PI 3-kinases are also known to possess protein kinase activity, with the ability to phosphorylate their own subunits [13, 14] . Evidence has been presented that the intrinsic phosphorylation of PI 3-kinase on Ser608 of the regulatory p85a subunit represents a form of negative feedback regulation [14] . This phosphorylation of Ser608 is stimulated by class 1a agonists [14, 15] and yet was observed to result in a dosedependent decrease in PI 3-K lipid kinase activity [13, 14] , an effect which was reversible by treatment with protein phosphatase 2A [13, 14] and alkaline phosphatase [13] . Studies with recombinant forms of PI 3-kinase indicate that there are differences in the protein kinase activity of different isoforms, for example 110a has a greater ability to phosphorylate p85 than p110b does [15] . Very little is known about the effect of oncogenic mutations in p110a on protein kinase activity, except that they retain the ability to phosphorylate Ser608 in p85a [8] . However, there has not been any detailed side-by-side comparison of the protein kinase activity of all PI 3-kinase isoforms, nor the susceptibility of this activity to different inhibitors. Interestingly some small molecules have been shown to differentially inhibit the lipid and protein kinase activities of PI 3-kinases [16, 17] raising the possibility that some of the new drugs being developed to target PI 3-kinases may do the same.
Exogenous targets of the protein kinase activity have also been identified. These include IRS-1 [18] [19] [20] , MEK-1 [21] , PDE3B [22] and 4EBP1 and H-Ras [15] . In most cases the functional consequences of these phosphorylation events have not been investigated but a recent study has provided evidence that phosphorylation of the GM-CSF/IL-3 bc receptor by p110a is functionally important in regulating cell survival in acute myeloid leukaemia cells [23] . This highlights the need to better understand the nature of the PI 3-kinase protein kinase activity towards exogenous substrates since it may play a role in normal cell regulation and/or tumourogenesis.
One argument against an in vivo role for the protein kinase activity of PI 3-kinase is that some studies to date have indicated it is manganese rather than magnesium dependent [13] [14] [15] and while magnesium is the most abundant divalent cation in cells [24] , manganese is only present as a trace element [25] .
Therefore to better understand the protein kinase activity of PI 3-kinase we have undertaken a comparison of the relative protein kinase activities of all the Class I PI 3-kinases as well as two common p110a oncogenic mutants (H1047R and E545K). These studies compared both the autophosphorylation and the exogenous kinase activity towards bic. Activities were determined in the presence of either Mn 2+ or Mg 2+ and we have also compared the effects on protein kinase activity of a range of known PI 3-kinase lipid kinase inhibitors.
Our studies provide the first evidence that oncogenic mutations of the p110a isoform of PI 3-kinase cause an upregulation of its protein kinase activity under physiologically relevant conditions. We describe distinct differences between wildtype and mutant p110a in relation to both the levels of p85a and p110 phosphorylation in buffers containing physiologically relevant Mg 2+ concentrations, and the resulting impact on lipid kinase. We go on to show that the oncogenic forms of p110a also have increased protein kinase activity towards an exogenous substrate (bic). We further describe the protein kinase activity of the remaining Class I isoforms, elucidating the effects that this phosphorylation has on lipid kinase activity. These studies provide evidence that the protein kinase activity of class-I PI 3-kinase is capable of playing an important regulatory role in the cell and may contribute to the oncogenic potential of mutant forms of PI 3-kinase.
Materials and Methods

Recombinant PI 3-Kinase Synthesis
All Class 1a isoforms and mutants were produced in-house by co-expressing full-length human p85a with the indicated human full-length catalytic subunit in Sf9 cells infected with a recombinant baculovirus containing coding sequences for both the p85a (p85a; Genbank accession NM_181523) and Class 1a p110 subunits (p110a, Genbank accession NM_006218; p110b, NM_006219; p110d, NM_005026) or Class 1b p110 subunit only (p110c, NM_002649).
Site directed mutagenesis of p110a to yield the oncogenic mutants was performed by using either complementary (overlapping sense and antisense) oligonucleotides containing sequence mismatches incorporating the desired point mutation, or back to back phosphorylated primers spanning the region to be mutated (with one primer containing the desired point mutation). For both methods resultant plasmids were sequenced to confirm the insertion of the desired mutations prior to generation of recombinant baculovirus. All p110 constructs (wildtype and mutant) contain an N-His6 rTEV tag used to purify the complex by IMAC before final purification by anion exchange on MonoQ column. The N-His6-tag was removed by overnight cleavage with rTEV at 4uC, as this has been previously shown to impact protein kinase activity [26, 27] .
Recombinant bic Production
Production and purification of the histidine-tagged recombinant bic protein encompassing amino acids 445-881 of the intracellular domain of GM-CSF/IL-3 bc has been previously described [23, 28] .
Inhibitors
Wortmannin and LY294002 were from Sigma-Aldrich (St Louis, USA); TGX-221 was from Symansis (Auckland, NZ); PIK-75, A66 and AS252424 were synthesized in-house as previously described [29, 30] .
Protein Kinase Assays
Unless otherwise stated, protein kinase assays were carried out in a buffer containing 50 mM NaCl, 20 mM Tris/Cl (pH 7.4), 0.1 mM Na-orthovanadate, 12 mM ATP, 5 mM DTT, 2 mCi c 33 P-ATP, and either 5 mM MgCl 2, or 5 mM MnCl 2 or both (as stated); Each reaction tube contained 0.5 mg kinase, 0.5 mg bic and inhibitors at stated concentrations. Unless otherwise stated, incubations were allowed to proceed for 20 minutes at 32uC and terminated by the addition of 5x electrophoresis sample buffer before complete denaturation at 99uC for 5 min. Components were separated by SDS PAGE, Coomassie-stained, dried and analysed by autoradiography (Molecular Dynamics Storm 680 PhosphorImager and quantified using ImageQuantTL software).
PP2A Treatment
Where stated, kinases were dephosphorylated using the catalytic portion of PP2A (Sigma P1618 from bovine kidney); 1 mg of kinase was incubated with 0.3 U of PP2A for 15 minutes at 30uC in a buffer containing 4 mM CaCl 2 , 10 mM MgCl 2 , 5 mM MnCl 2 , 50 mM NaCl, 20 mM Tris/Cl (pH 7.4) and 5 mM DTT.
Lipid Kinase Assays
To verify the impact of phosphorylation on lipid kinase activity, kinases were either pretreated with ATP (phosphorylated) or PP2A (unphosphorylated) before determining lipid kinase activity using phosphoinositol (PI) as a substrate. More specifically, kinases were either treated according to the Protein Kinase Assay (for 1 hour at 37uC without c 33 P-ATP) or PP2A Treatment methods outlined above before the addition of EDTA to a final concentration of 2 mM EDTA; 10 mL of kinase (equivalent to 0.5 mg) was mixed with 90 mL buffer containing 40 mM Tris/Cl, 200 mM NaCl, 1 mM EDTA (pH 7.4). Each reaction point consisted of 20 mL of this kinase mixed with 10 mL of 1 mg/mL PI (Lipid Products, Surrey UK) in 10 mM Tris/Cl, 1 mM EDTA (pH 7.4), and 30 mL of ATP mix (10 mM MgCl 2 , 200 mM ATP, 1 mCi c 33 P-ATP). The reaction was allowed to proceed for 1 hour at room temperature and stopped with 100 mL of 1 M HCl, before chloroform lipid extraction as previous (Method 2 described in [31] ) with minor alterations described here. Specifically the re-extraction buffer consisted of 50:50 methanol/1 M HCl and the dried lipid was resuspended in 30 mL of chloroform: methanol (4:1 v/v). TLC plates were pre-treated with a solution containing 8 mM oxalic acid and 1 mM EDTA (pH 8) in MQ H 2 O/ethanol (3:1 v/v), and allowed to dry at room temperature overnight. Lipids were separated on the TLC plates using propan-1-ol/glacial acetic acid/MQ H 2 O (65:4:31 v/v). Assay results were analysed by autoradiography (Molecular Dynamics Storm 680 PhosphorImager and quantified using ImageQuantTL software).
Lipid Kinase IC 50 Determination
IC 50 values were determined using the PI3K (human) HTRF Assay (Millipore, #33-016). All PI 3-K isoforms were made inhouse and used in the range of their EC 65-80 titration (18 ng/mL for H1047R, 6.5 ng/mL for E545K, 50 ng/mL for p110a, 400 ng/mL for p110b, 65 ng/ml for p110d and 400 ng/mL for p110c). Drugs were dissolved in DMSO and serially diluted in the same. Final DMSO concentration in assay was 2.5%.
Results
Characterisation of Lipid Kinase Activity in the Presence and Absence of PI 3-kinase Autophosphorylation
Previous studies using endogenous purified proteins have shown that phosphorylation of class-I PI 3-K reduces the lipid kinase activity of all isoforms except p110c [13] [14] [15] 32, 33] , although more recently a study comparing wildtype and mutant p110a reported that p85a phosphorylation had no impact on lipid kinase activity [34] . Here we have performed a comprehensive side-by-side comparison of all Class-I PI 3-kinases as well as two common oncogenic mutants of p110a ( Figure 1) . Importantly the presence of epitope tags is known to affect the activity of recombinant PI 3-kinases [26, 27] so our recombinant proteins have the tag cleaved to minimize any such effects. Since it has been reported that there are pre-existing high levels of phosphorylation in the Sf9-produced recombinant protein [35] , we first pre-treated the kinase with protein phosphatase 2A, and then carried out incubations in the presence and absence of ATP. These experiments showed a clear effect of protein phosphorylation on lipid kinase activity ( Figure 1) , with wildtype and mutant p110a and p110b exhibiting .80% knockdown in lipid kinase activity with phosphorylation, while p110d and c were less impacted. While these results contrast to the recent report of Layton et al (2012) [34] , the results for p110a and p110b are in agreement with previous findings [13, 14, 33] . The moderate 60% knockdown of p110d lipid kinase activity varies somewhat from previous findings [32] which demonstrated .90% knockdown of lipid kinase activity with autophosphorylation. Moreover previous studies suggested there would be no change in lipid kinase activity for p110c following autophosphorylation [36, 37] , and while p110c was less impacted than p110a and b, in our hands it was still reduced to less than 40% activity. Importantly we find that the lipid kinase activity of p110a mutants is reduced following autophosphorylation by the same degree as wildtype p110a (Figure 1) .
Divalent Cation Dependence
One of the earliest reports of the protein kinase activity of PI 3-kinase showed that this activity was dependent on Mn 2+ [14] , and this was reiterated by Dhand et al. (1994) [13] . While subsequent studies have been carried out comparing the Mn/Mg dependent autophosphorylation of p110a and p110d [32] and p110a and p110b [33] , a comprehensive investigation of all the isoforms has never been completed. Furthermore, no studies have been carried out to test the ability of different PI 3-kinase isoforms to phosphorylate the exogenous substrate bic. Therefore we compared the protein kinase activities of all the isoforms and the two oncogenic mutants in the presence of Mn 2+ , Mg 2+ or both ( Figure 2A) .
We observe autophosphorylation of p110 subunit by p110a wildtype and mutants, and p110b in the presence of Mg 2+ , albeit much reduced in comparison to kinase incubated with Mn 2+ , while p110c retained 100% activity in Mg 2+ only buffer. We only observe significant p85 phosphorylation in the proteins containing wildtype or oncogenic p110a (Figure 2A) . Of particular interest, phosphorylation of the exogenous substrate bic was observed in the presence of Mg 2+ for all isoforms but with the relative level of phosphorylation being different for the different isoforms. p110b and the oncogenic mutants exhibited the most activity (approaching 2-fold more activity than p110a), while p110 c and p110a had equal activity, and p110d very little (Figure 2A and 2B) . The largest observable difference between the two oncogenic forms of PI 3-kinase was that autophosphorylation of p110 remained strong in the presence of Mg 2+ for H1047R mutant but was not present in the E545K mutant and wildtype p110a ( Figure 2C ). The significance of this remains to be elucidated.
Lipid Kinase Inhibitors also Inhibit the Protein Kinase Activity of PI 3-kinase
We also tested the effect of different small molecules known to inhibit the lipid kinase activity of PI 3-kinases. We first challenged all the isoforms and mutants with a fixed concentration of the panspecific inhibitors LY294002 and wortmannin, p110a-specific inhibitors A66 and PIK-75, the p110b-specific inhibitor TGX221, and the p110c inhibitor AS252424. All inhibitors were initially screened at a final concentration of 10 mM except LY294002, which was used at a final concentration of 100 mM. A66 and AS252424 follow the same pattern of isoform selectivity as seen in their lipid kinase activities ( Figure 3A) . Interestingly p110b protein kinase activity was largely resistant to all inhibitors except PIK-75, with TGX221 being notably ineffective despite it being known as a p110b selective lipid kinase inhibitor. Wortmannin was also surprisingly ineffective. Our results clearly showed that PIK-75 was the most effective inhibitor, knocking down the p110 and p85 phosphorylation of all kinases by $90% even though it was previously described as a p110a selective inhibitor ( Figure 3A) .
To further understand these results we generated IC 50 inhibition curves for PIK-75, LY294002, A66 and wortmannin against p110a and the oncogenic mutants ( Figure 3B and Table 1 ). Interestingly the IC 50 's generated for the protein kinase and lipid kinase inhibition were broadly in the same range for PIK-75, LY294002 and A66 (Table 1 and 2) . However, the IC 50 of wortmannin against the protein kinase activity was significantly higher than the lipid kinase activity in the conditions tested ( Figure 3B , Table 1 and 2).
Discussion
PI 3-K has been recognized as a dual lipid/protein kinase since the seminal papers of Carpenter et al. (1993) and Dhand et al. (1994) [13, 14] . While the lipid kinase activity is acknowledged as critical for many cellular functions, the physiological significance of the protein kinase activity has long been questioned due to its Mn 2+ dependency and lack of in vivo relevance. However, we have recently shown that PI 3-K protein kinase activity is deregulated in .80% of primary AML patient samples [23, 38] and that PI 3-Kmediated phosphorylation of the GM-CSF/IL-3 receptors regulates cell survival [23] . These findings have reinitiated interest in this area. Here we have systematically studied the in vitro protein kinase activity of all human class-1 PI 3-kinase isoforms as well as 2 common gain-of-function oncogenic mutants of p110a, the catalytic-domain H1047R mutant and the helical-domain mutant E545K. We further evaluate and discuss their ability to autophosphorylate as well as phosphorylate an exogenous substrate (GM-CSF/IL-3 bc receptor-derived bic peptide), in the presence and absence of Mn 2+ and Mg 2+ , and the impact of a range of ATPcompetitive inhibitors on their protein kinase activity.
With the exception of p110d, our results show that all the forms of PI 3-K investigated retain some level of protein kinase activity in the presence of Mg 2+ alone, with p110c and the H1047R mutant retaining significantly more protein kinase activity than the other forms. Divalent cations such as Mg 2+ and Mn 2+ are required to coordinate the phosphates in ATP to give it the correct conformation for catalytic reactions [39] , and while magnesium is the most abundant divalent cation in cells [24] , manganese is only present as a trace element at mM concentrations, with free cytoplasmic concentrations further reduced due to intracellular compartmentalization [25] . Previous evidence indicated that the protein kinase activity of PI 3-K was Mn 2+ dependent [13] [14] [15] , which cast doubt over the in vivo role of this enzyme activity. Therefore our observation of protein kinase activity in the presence of only Mg 2+ (especially the oncogenic mutants of p110a) provides evidence that this activity could be important in vivo.
All the forms of PI 3-K, again excepting p110d, were effective to different degrees with regards to phosphorylating the exogenous substrate, bic. The oncogenic forms of PI 3-K have increased protein kinase activity compared to wildtype p110a, and these mutants, together with p110b and p110c showed strong phosphorylation of bic. The increased protein kinase activity against an exogenous substrate indicates that these forms could possibly phosphorylate other substrates, including those contributing to oncogenesis. This could in part explain the oncogenic effects seen with overexpression of p110b and p110c in cell models [40, 41] , and why cellular overexpression of these alone can contribute to tumourogenesis [42, 43] . It is important to note that while we have shown that PI 3-K-mediated phosphorylation of the GM-CSF/IL-3 receptors regulates cell survival [23] , it seems likely that other p110-mediated phosphorylation events also occur, since evidence has been presented that PI 3-kinase phosphorylates a range of signaling molecules including IRS-1 [18] [19] [20] , 4EBP1 and H-Ras [15] . To date these phosphorylation events have been poorly characterized but it remains possible that these might contribute to activation of signaling pathways in cancer.
In general p110a and the E545K mutant showed strong p85 phosphorylation with little p110 autophosphorylation, while p110b and p110c showed high p110 phosphorylation. The H1047R mutant maintained the strong p85 phosphorylation as seen with the wildtype PI 3-Ka isoform, but also showed elevated levels of p110 phosphorylation, approaching those of p110b. The significance of this increase in p110 phosphorylation in the H1047R mutant is not clear, especially as the lipid kinase activity of both oncogenic isoforms and wildtype p110a are inhibited by pre-phosphorylation to a similar extent. However since the level of reduction in the lipid kinase activity is similar in all three forms of p110a and p110b, it demonstrates, in agreement with Layton et al (2012) [34] , that the increased lipid kinase activity in H1047R and E545K are not due to any reduction in auto-regulatory protein kinase activity. This further reinforces the hypothesis that the area where the increased protein kinase activity might have the most impact on cellular function is in the phosphorylation of exogenous substrates.
Our observations regarding the potency of PIK-75 relative to other inhibitors (TGX221 and AS252424) support our previous findings showing PIK-75 preferential inhibition of Ser585 phosphorylation in the GM-CSF/IL-3 receptors [23] . The fact that the inhibition of lipid and protein kinase activity by small molecules does not always directly correlate is also interesting and has potential implications for the use of PI 3-K inhibitors in the clinic, as it may explain the functional differences between different inhibitors in some contexts. For example, our finding that LY294002 is more effective at blocking the protein kinase activity of PI 3-K relative to wortmannin supports the unexpected observation that LY294002 was more effective than wortmannin at blocking the anti-apoptotic effect of GM-CSF [44] . However Figure 3 . Effects of pan-and isoform-specific inhibitors on protein kinase activity. A) Representative autoradiograph scans showing relative intensity of phosphorylation in the presence of pan-inhibitors LY294002 and wortmannin, and p110a-specific inhibitors A66 and PIK-75, p110b-specific inhibitor TGX221 and p110c-specific inhibitor AS252424. Graphs summarise the results of N$3 experiments for H1047R (black bars) and E545K (white bars) to p110a (hatched bars), p110b (cross-hatched bars) and p110c (horizontal stripe bars) B) IC 50 curves for selected inhibitors PIK-75, LY294002, A66 and wortmannin against p110a, H1047R and E545K. doi:10.1371/journal.pone.0071337.g003 detailed explanation for the observed differences will require in depth structural studies to define how protein substrates interact with the kinase domain. In summary, we compared the in vitro protein kinase activity of all human class-1 PI 3-kinase isoforms as well as 2 common gainof-function oncogenic mutants of p110a, H1047R and E545K. We found that the oncogenic mutants have stronger protein kinase activity as measured by autophosphorylation, as well as phosphorylation of the exogenous substrate, bic. Furthermore we show that the oncogenic mutants (especially H1047R) are not as reliant on Mn 2+ and retain significantly more protein kinase activity in the presence of Mg 2+ alone. We demonstrate that the protein kinase activity of the wildtype and oncogenic forms of p110a are all inhibited by small molecules known to inhibit the lipid kinase activity of p110a; including LY294002, A66 and to a lesser degree wortmannin. However, inhibition was particularly pronounced with PIK-75. In addition we showed that p110b and p110c exogenous and auto-phosphorylation was retained in the presence of Mg
2+
, and these isoforms were relatively resistant to inhibition by all inhibitors except PIK-75 (and AS252424 for p110c). In contrast p110d was Mn 2+ dependent, only weakly phosphorylated bic and was fully suppressed by all inhibitors used. Since PI 3-K phosphorylates exogenous substrates and has been linked to changes in lipid kinase activity and possible activation of alternate signaling pathways [45] , this increased protein kinase activity of E545K and especially H1047R in the presence of Mg 2+ could have implications for the physiological activity of PI 3-K, especially in tumours carrying these mutations. 
